---
id: "contrarian-amcs-as-pharma"
type: "contrarian-insight"
source_timestamps: ["§ 1. Embrace a new model for accelerating drug development.", "§ 4. Extend AMC research investments beyond early-stage science."]
tags: ["business-models", "paradigm-shift", "contrarian-insight"]
related: ["concept-in-house-accelerators", "concept-amc-strategic-financing"]
challenges: "The conventional view that academia and commercial pharmaceutical development should remain strictly separated by the technology-transfer 'wall'."
sources: ["tail2"]
sourceVaultSlug: "hbr-seg-tail2"
originDay: 2
articleStem: "hbr-tail-131-medical-drug-discovery"
sourceUrl: "https://hbr.org/2026/04/u-s-medical-centers-need-a-new-model-for-drug-discovery-and-development"
sourceTitle: "U.S. Medical Centers Need a New Model for Drug Discovery and Development"
---
# Contrarian: AMCs Must Act Like Pharma and VC Firms

**Contrarian insight.** Traditionally, academic medical centers view themselves strictly as hubs for **basic science, education, and patient care**, leaving commercialization to the private sector. The authors argue the opposite: to survive, AMCs must **internalize pharmaceutical operations** (portfolio management, active clinical development — [[concept-in-house-accelerators]]) **and act as venture capitalists** (strategic financing, incubation sandboxes — [[concept-amc-strategic-financing]]).

**What it challenges:** the conventional view that academia and commercial pharmaceutical development should remain **strictly separated by the technology-transfer "wall"** ([[prereq-tech-transfer]]).

**Counter-perspective (enrichment):** the "pharma-like AMC" model may **not generalize** — existing academic drug-development success stories often focus on **rare or neglected diseases** where industry incentives are weak, suggesting university-led development may be best as a **complement to pharma rather than a wholesale replacement**. This tension is the substance of [[question-mission-fidelity]].